Ruetsch Charles, Davis Tigwa, Liberman Joshua N, Velligan Dawn I, Robinson Delbert, Jaeger Chris, Carpenter William, Forma Felica
Health Analytics, LLC, Columbia, MD, USA.
Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Neuropsychiatr Dis Treat. 2021 Dec 16;17:3715-3726. doi: 10.2147/NDT.S318344. eCollection 2021.
Psychiatric prescribers (prescribers) typically assess medication adherence by patient or caregiver self-report. Despite likely clinical benefit of a new digital medicine technology, the role of specific prescriber attitudes, behaviors, and experiences in the likelihood of adoption is unclear.
To identify prescriber characteristics that may affect adoption of the ingestible event marker (IEM) platform.
A survey of prescribers treating seriously mentally ill patients was conducted. Factor analysis was performed on 11 items representing prescriber characteristics believed to be related to endorsement of the IEM platform. Four factors were extracted. Regression analysis was used to test the strength of the relationships between the factors and likelihood of adoption of the IEM platform.
A total of 131 prescribers completed the survey. Most (84%) agreed that visits allow enough time to monitor adherence. Factor analysis revealed four underlying dimensions: 1) perspectives on the value of adherence; 2) concerns about measuring adherence; 3) views toward digital health technologies; and 4) views on payer role/reimbursement. Factors 1 and 3 were related to gender, the belief that computerization benefits prescribers, the presence of office support staff, and the belief that new digital medicine (DM) technology will be cost prohibitive. Willingness to adopt the IEM platform was related to gender (p < 0.05) and perspectives on the value of adherence (p < 0.05), with those scoring higher on that measure also being more likely to adopt.
Psychiatric prescribers are concerned about medication adherence, perceive current monitoring tools to be problematic, and are open to using digital technologies to improve accuracy of adherence assessment. Relationships among prescriber characteristics, beliefs, and experiences should be considered when developing educational materials, particularly when the goal is to encourage adoption and use of the IEM platform.
精神科开方者（开方者）通常通过患者或护理人员的自我报告来评估药物依从性。尽管一种新的数字医学技术可能具有临床益处，但特定开方者的态度、行为和经验在采用可能性方面所起的作用尚不清楚。
确定可能影响可摄入事件标记物（IEM）平台采用情况的开方者特征。
对治疗严重精神疾病患者的开方者进行了一项调查。对代表被认为与IEM平台认可相关的开方者特征的11个项目进行了因子分析。提取了四个因子。使用回归分析来检验这些因子与IEM平台采用可能性之间关系的强度。
共有131名开方者完成了调查。大多数（84%）人认为就诊有足够时间监测依从性。因子分析揭示了四个潜在维度：1）对依从性价值的看法；2）对测量依从性的担忧；3）对数字健康技术的看法；4）对支付方角色/报销的看法。因子1和因子3与性别、认为计算机化对开方者有益、办公室有支持人员以及认为新的数字医学（DM）技术成本过高有关。采用IEM平台的意愿与性别（p < 0.05）和对依从性价值的看法（p < 0.05）有关，在该测量中得分较高的人也更有可能采用。
精神科开方者关注药物依从性，认为当前的监测工具存在问题，并愿意使用数字技术来提高依从性评估的准确性。在开发教育材料时，应考虑开方者特征、信念和经验之间的关系，特别是当目标是鼓励采用和使用IEM平台时。
